Biomerica Past Earnings Performance
Past criteria checks 0/6
Biomerica's earnings have been declining at an average annual rate of -14.1%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 2.9% per year.
Key information
-14.1%
Earnings growth rate
-4.4%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 2.9% |
| Return on equity | -115.3% |
| Net Margin | -111.9% |
| Last Earnings Update | 31 Aug 2024 |
Recent past performance updates
Recent updates
Is Biomerica (NASDAQ:BMRA) In A Good Position To Deliver On Growth Plans?
Dec 20
Here's Why We're Watching Biomerica's (NASDAQ:BMRA) Cash Burn Situation
Aug 31We're Keeping An Eye On Biomerica's (NASDAQ:BMRA) Cash Burn Rate
Mar 04Amazon starts selling Biomerica's Aware Breast Self Exam device, EZ Detect test
Sep 29Biomerica: One To Watch Closely For The Future, But From The Sidelines For Now
Sep 09Biomerica reports FY results
Aug 29Biomerica stock jumps after Walmart to begin selling co's Aware Breast Self Exam device
Jul 14Most Shareholders Will Probably Find That The CEO Compensation For Biomerica, Inc. (NASDAQ:BMRA) Is Reasonable
Dec 03Biomerica (NASDAQ:BMRA) Is In A Good Position To Deliver On Growth Plans
Dec 02Is Biomerica Stock A Buy Or Sell After Q4 Earnings? Catalysts To Watch Into 2022
Sep 15Biomerica (BMRA) Investor Presentation - Slideshow
Jun 14Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth
Jun 13Biomerica, Inc.'s (NASDAQ:BMRA) Profit Outlook
Apr 04Should You Review Recent Insider Transactions At Biomerica, Inc. (NASDAQ:BMRA)?
Mar 08Companies Like Biomerica (NASDAQ:BMRA) Are In A Position To Invest In Growth
Feb 10The Biomerica (NASDAQ:BMRA) Share Price Has Soared 405%, Delighting Many Shareholders
Jan 15
Biomerica soars as its COVID-19 antigen test wins European nod
Jan 12When Will Biomerica, Inc. (NASDAQ:BMRA) Become Profitable?
Dec 20Biomerica clinical trial for IBS nears enrollment completion
Dec 09How Much Does Biomerica's (NASDAQ:BMRA) CEO Make?
Nov 23Revenue & Expenses Breakdown
How Biomerica makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Aug 24 | 6 | -6 | 6 | 1 |
| 31 May 24 | 5 | -6 | 5 | 1 |
| 29 Feb 24 | 5 | -6 | 5 | 2 |
| 30 Nov 23 | 6 | -6 | 5 | 2 |
| 31 Aug 23 | 5 | -6 | 6 | 2 |
| 31 May 23 | 5 | -7 | 6 | 2 |
| 28 Feb 23 | 10 | -7 | 6 | 2 |
| 30 Nov 22 | 16 | -6 | 6 | 2 |
| 31 Aug 22 | 19 | -5 | 6 | 2 |
| 31 May 22 | 19 | -5 | 6 | 2 |
| 28 Feb 22 | 15 | -4 | 5 | 2 |
| 30 Nov 21 | 11 | -7 | 5 | 2 |
| 31 Aug 21 | 7 | -7 | 5 | 2 |
| 31 May 21 | 7 | -7 | 6 | 2 |
| 28 Feb 21 | 9 | -6 | 5 | 3 |
| 30 Nov 20 | 6 | -5 | 4 | 2 |
| 31 Aug 20 | 7 | -4 | 3 | 2 |
| 31 May 20 | 7 | -2 | 2 | 2 |
| 29 Feb 20 | 5 | -3 | 2 | 2 |
| 30 Nov 19 | 5 | -2 | 2 | 2 |
| 31 Aug 19 | 5 | -2 | 2 | 2 |
| 31 May 19 | 5 | -2 | 2 | 2 |
| 28 Feb 19 | 5 | -2 | 2 | 2 |
| 30 Nov 18 | 5 | -2 | 2 | 2 |
| 31 Aug 18 | 5 | -2 | 2 | 2 |
| 31 May 18 | 6 | -1 | 2 | 1 |
| 28 Feb 18 | 6 | -1 | 2 | 1 |
| 30 Nov 17 | 6 | -1 | 2 | 1 |
| 31 Aug 17 | 6 | -1 | 2 | 1 |
| 31 May 17 | 6 | -1 | 2 | 1 |
| 28 Feb 17 | 6 | -2 | 2 | 1 |
| 30 Nov 16 | 6 | -2 | 2 | 1 |
| 31 Aug 16 | 5 | -1 | 2 | 1 |
| 31 May 16 | 5 | -1 | 2 | 1 |
| 29 Feb 16 | 5 | 0 | 2 | 1 |
| 30 Nov 15 | 5 | 0 | 1 | 1 |
| 31 Aug 15 | 5 | 0 | 1 | 1 |
| 31 May 15 | 5 | 0 | 1 | 1 |
| 28 Feb 15 | 5 | 0 | 2 | 1 |
| 30 Nov 14 | 5 | 0 | 2 | 0 |
| 31 Aug 14 | 5 | 0 | 2 | 0 |
| 31 May 14 | 5 | 0 | 2 | 0 |
| 28 Feb 14 | 5 | 0 | 1 | 0 |
Quality Earnings: BMRA is currently unprofitable.
Growing Profit Margin: BMRA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BMRA is unprofitable, and losses have increased over the past 5 years at a rate of 14.1% per year.
Accelerating Growth: Unable to compare BMRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BMRA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).
Return on Equity
High ROE: BMRA has a negative Return on Equity (-115.26%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 14:37 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/08/31 |
| Annual Earnings | 2024/05/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biomerica, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nathan Weinstein | Aegis Capital Corporation |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Kyle Bauser | Colliers Securities |